We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...
Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This ...
Prothena is evaluating PRX012 — a wholly owned investigational next-generation subcutaneous, single-injection once-monthly antibody delivered subcutaneously targeting a key epitope at the N-terminus ...
Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q3 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc.
Hosted on MSN21h
Ozempic and Viagra, among the more than 80 drugs expected to work against Alzheimer's in the coming yearsIn recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...
Alzheimer's disease is the most common cause of dementia in the elderly and is characterized by abnormal deposits of amyloid-beta and tau proteins in the brain. This disease has a ...
Analyst Jason Butler of JMP Securities reiterated a Buy rating on Prothena (PRTA – Research Report), retaining the price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback